Your path to a healthier lifestyle starts with a single, informed step
The image below demonstrates the effects of GLP-1 agonists on various systems: The most common adverse drug reactions reported with GLP-1 agonists are as follows: These include: In New Zealand, dulaglutide (Trulicity) was the first approved GLP-1 agonist, made available for the treatment of Type 2 Diabetes in 2021
Jason Shafrin Jason Shafrin Published Jun 15, 2026 That is the title of a recent white paper written by myself and Kristy Piccinini alongside a team from the Health and Fitness Association (Greta Wagner, Amy Bantham, Ken Griffin, Richard Beddie, Zach Weston, Cameron Saunders)
Thermogenesis: Tirzepatide can stimulate the energy expenditure of the body through thermogenesis, encouraging calorie burn and fat loss
Heartburn and acid reflux were reported less frequently, typically in fewer than 5% of trial participants across all dose levels